Biogen’s Hemophilia Spin: Prelude to a Takeover?

Today’s announcement that Biogen ( BIIB ) plans to spin off its hemophilia business into a stand-alone company has more than a few analysts and investors scratching their heads. Among the many questions: Is this a prelude to a takeover?
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.